Cullinan Therapeutics Inc (CGEM)

Jul 23, 2025

What drives Cullinan Therapeutics Inc. stock priceAccelerated investment success - Autocar Professional

Jul 23, 2025

Jul 23, 2025

Is Cullinan Therapeutics Inc. a good long term investmentUnbelievable profit margins - Autocar Professional

Jul 23, 2025

Jul 22, 2025

Breakthrough Lung Cancer Treatment: Zipalertinib Trial Results Reveal New Hope for Hard-to-Treat EGFR Mutations - Stock Titan

Jul 22, 2025

Jul 19, 2025

What analysts say about Cullinan Therapeutics Inc. stockExplosive market performance - jammulinksnews.com

Jul 19, 2025

Jul 18, 2025

Cullinan Therapeutics Inc. Stock Analysis and ForecastExceptional stock performance - jammulinksnews.com

Jul 18, 2025

Jul 15, 2025

Zipalertinib's NDA Submission: Can Cullinan Therapeutics Finally Cash In on Its Breakthrough? - AInvest

Jul 15, 2025

Jul 15, 2025

Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst - Seeking Alpha

Jul 15, 2025

Jul 15, 2025

How Cullinan Therapeutics Inc. stock performs during market volatilityChart Breakout Alert - Newser

Jul 15, 2025

Jul 15, 2025

Why Cullinan Therapeutics Inc. stock attracts strong analyst attentionBalanced Risk Reward Portfolio - Newser

Jul 15, 2025

Jul 15, 2025

What makes Cullinan Therapeutics Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser

Jul 15, 2025

Jul 14, 2025

Disc Medicine Appoints Nadim Ahmed To Board - citybiz

Jul 14, 2025

Jul 14, 2025

Disc Medicine Appoints Nadim Ahmed to its Board of Directors - The Manila Times

Jul 14, 2025

Jul 10, 2025

We're Keeping An Eye On Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Rate - Yahoo Finance

Jul 10, 2025

Jul 09, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Jul 09, 2025

Jul 03, 2025

Cullinan Oncology stock rating reiterated at Buy by Clear Street - Investing.com Australia

Jul 03, 2025

Jun 30, 2025

Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell Microcap Growth Index - MarketScreener

Jun 30, 2025

Jun 21, 2025

Assenagon Asset Management S.A. Cuts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 21, 2025

Jun 20, 2025

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC - insights.citeline.com

Jun 20, 2025

Jun 17, 2025

Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld MedTech

Jun 17, 2025

Jun 17, 2025

Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $30.00 - Defense World

Jun 17, 2025

Jun 12, 2025

Cullinan Management Holds Annual Stockholders Meeting - TipRanks

Jun 12, 2025

Jun 12, 2025

Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset - BioWorld MedTech

Jun 12, 2025

Jun 12, 2025

California State Teachers Retirement System Lowers Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 12, 2025

Jun 12, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Now Covered by Analysts at Stifel Nicolaus - Defense World

Jun 12, 2025

Jun 11, 2025

Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating a - GuruFocus

Jun 11, 2025

Jun 11, 2025

Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating and $22 Price Target | CGEM Stock News - GuruFocus

Jun 11, 2025

Jun 11, 2025

Stifel Recommends Buy Rating for Cullinan Therapeutics (CGEM) | CGEM Stock News - GuruFocus

Jun 11, 2025

Jun 10, 2025

Two Sigma Investments LP Has $514,000 Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 10, 2025

Jun 10, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 10, 2025

Jun 08, 2025

Squarepoint Ops LLC Sells 11,673 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 08, 2025

Jun 08, 2025

The week in pharma: action, reaction and insight – week to June 6 - The Pharma Letter

Jun 08, 2025

Jun 07, 2025

Two Sigma Advisers LP Grows Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 07, 2025

Jun 05, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio - Contract Pharma

Jun 05, 2025

Jun 05, 2025

Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix By Stocktwits - Investing.com India

Jun 05, 2025